	Application No.	Applicant(s)
Notice of Allowability	• •	Applicant(s)
	09/924,340	BEJANIN ET AL.
	Examiner	Art Unit
	Marina Miller	1631
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>11/14/2005</u> .		
2. The allowed claim(s) is/are 34-37 and 47-49.		
 3. Acknowledgment is made of a claim for foreign priority under a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents 	been received. been received in Application No	
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. □ Notice of References Cited (PTO-892)	5 Notice of Informal F	Potent Application (DTO 452)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary	Patent Application (PTO-152)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08	Paper No./Mail Da	te <u>1/3/06</u> .
Paper No./Mail Date 4. ⊠ Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9. Other	
	_	

DETAILED ACTION

Examiner's amendment

Authorization for this examiner's amendment was given in a telephone interview with

Frank C. Eisenschenk, an attorney for applicants, on 01/03/2006.

Cancel claims 38-40.

The application's title has been changed by the examiner to reflect the matter claimed in

the allowed claims. The new title is "An isolated human vCOL16A1 polypeptide and fragments

thereof."

Examiner's Comments Regarding Requirement for Deposit of Biological Material

Applicants are required to comply with 37 C.F.R. 1.808, particularly section (a)(2),

regarding availability of deposited material to the public.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

Amendments and arguments filed by applicants on 11/14/2005 have overcome rejections

under 35 U.S.C. 101, 102, and 112, first and second paragraphs.

Applicants argue that the instant invention has patentable utility because polypeptide

SEQ ID NO: 58 represents a splice variant of the human collagen. The claimed splice variant

exhibits most of the characteristics of the collagen proteins, which can be used as injectable

biomaterial or in cosmetic compositions. The claimed splice variant of the human collagen, which exhibits structural characteristics of the collagens, has patentable utility because all members of the collagen family exhibit similar properties (i.e., these proteins constitute the major extracellular matrix components of connective tissue) and may be used in cosmetic compositions and as an injectable material.

In light of the applicants' amendment, the rejection of claims 37 and 49 under 35 U.S.C. 112, first (new matter) and second paragraph, and 102(b) is withdrawn.

Any comments considered necessary by applicants must be submitted no later than the payment of the issue fee and, to avoid processing delay, should preferably accompany the issue fee. Such submission should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Claims 34-37 and 47-49 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marina Miller whose telephone number is (571)272-6101. The examiner can normally be reached on 8-5, M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, Ph. D., can be reached on (571)272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/924,340

Art Unit: 1631

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Marina Miller Examiner Art Unit 1631

MM

MARJORIE A. MORAN PRIMARY EXAMINED

Sayous a - Moran